15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$103M | — | — | -$95M | $2M | $31M |
| 2024 | — | -$79M | — | — | -$73M | $2M | $62M |
| 2023 | $1M | -$47M | 100.0% | -2855.0% | -$38M | $2M | $9M |
| 2022 | $0 | -$11M | — | — | -$11M | — | $21M |
| 2022 | $11M | -$7M | 0.0% | -59.5% | -$8M | — | $56M |
| 2021 | $10M | -$3M | 50.9% | -34.3% | -$3M | — | $64M |
| 2020 | $10M | -$3M | 52.9% | -35.9% | -$4M | — | $2M |
| 2019 | $7M | -$5M | 41.7% | -71.8% | -$5M | — | $5M |
| 2018 | $6M | -$7M | 31.1% | -113.6% | -$6M | — | $3M |
| 2017 | $5M | -$6M | 17.6% | -132.5% | -$6M | — | $6M |
| 2016 | — | -$5M | — | — | -$4M | — | $10M |
| 2015 | — | -$4M | — | — | — | — | $5M |
| 2014 | — | -$6M | — | — | — | — | $8M |
| 2013 | — | -$4M | — | — | -$3M | — | $3M |
| 2012 | — | -$3M | — | — | -$3M | — | $3M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$26M | — | — | -$38M | $2M | $54M |
| Dec '25 | — | -$37M | — | — | -$30M | $2M | $31M |
| Sep '25 | — | -$26M | — | — | -$18M | $2M | $27M |
| Jun '25 | — | -$21M | — | — | -$21M | $2M | $29M |
| Mar '25 | — | -$18M | — | — | -$26M | $2M | $44M |
| Dec '24 | — | -$40M | — | — | -$41M | $2M | $62M |
| Sep '24 | — | -$15M | — | — | -$26M | $2M | $226M |
| Jun '24 | — | -$12M | — | — | -$10M | $2M | $252M |
| Mar '24 | — | -$12M | — | — | $5M | $2M | $142M |
| Dec '23 | -$4M | -$25M | 1.0% | 306.9% | -$9M | $2M | $9M |
| Sep '23 | $2M | -$10M | 38.7% | -510.7% | -$10M | $2M | $18M |
| Jun '23 | $2M | -$11M | 16.5% | -650.3% | -$9M | $2M | $28M |
| Mar '23 | $2M | -$371000 | 26.6% | -533.4% | -$10M | $2M | $36M |
| Dec '22 | -$7M | -$3M | 39.0% | 13.8% | -$4M | — | $21M |
| Sep '22 | $2M | -$4M | 24.1% | -245.1% | -$2M | — | $19M |
| Jun '22 | $3M | -$2M | 37.0% | -84.1% | -$3M | — | $56M |
| Mar '22 | $3M | -$1M | 49.5% | -47.3% | -$1M | — | $59M |
| Dec '21 | $3M | -$2M | 43.3% | -58.1% | -$1M | — | $60M |
| Sep '21 | $3M | -$2M | 40.1% | -88.7% | -$2M | — | $62M |
| Jun '21 | $3M | -$1M | 49.7% | -40.3% | -$1M | — | $64M |
How the market has priced CATX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Perspective Therapeutics, Inc.'s revenue has declined 24.7% per year. These are computed facts, not advice.
As of FY2025, Perspective Therapeutics, Inc. reported $2M of total debt against $31M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.